All studies
Active not recruitingPHASE2INTERVENTIONAL

Phase 2b Open-Label Repeat Kidney Biopsy Study

IgA nephropathy is an autoimmune condition where an antibody called IgA builds up inside the filters of the kidneys, causing inflammation and gradual damage over time. This phase 2 clinical trial is testing whether an investigational medicine called sibeprenlimab can reduce these harmful deposits and protect kidney function. Because this is an open-label study, everyone taking part will receive the active study medicine. Over the course of 52 weeks (one year), doctors will monitor your health closely through regular check-ups, blood and urine tests, and a follow-up kidney biopsy to see how the tissue looks under a microscope. The trial is open to adults aged 18 and older who have a confirmed diagnosis of IgA nephropathy and relatively stable kidney function. The findings will help researchers understand if sibeprenlimab can safely slow or prevent long-term kidney damage.

At a glance

Status
Active not recruiting
Phase
PHASE2
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Enrolment target
56
Start
05 Dec 2024
Estimated completion
28 Dec 2028

What is this study about?

IgA nephropathy, sometimes called Berger's disease, happens when an immune protein that normally fights infections builds up inside the small filtering units of your kidneys. Over time, this build-up can cause irritation, swelling, and scarring, which makes it harder for the kidneys to clean your blood properly.

Sibeprenlimab is a new medicine designed to block specific signals in the immune system that trigger this protein build-up. In this study, doctors want to find out whether taking sibeprenlimab for one year can directly clear or reduce the protein deposits within the kidney tissue itself, helping to calm inflammation.

Finding new, targeted treatments for IgA nephropathy is vital because current therapies do not work well for everyone, and some people face long-term kidney failure. By comparing a kidney sample taken at the end of the year to samples taken before treatment, this study aims to show whether sibeprenlimab can truly protect kidney tissue from ongoing harm.

Key takeaways

  • Tests an experimental drug called sibeprenlimab for adults with IgA nephropathy.
  • Open-label trial: every person enrolled receives the active study drug.
  • Lasts around 52 weeks and includes regular clinic visits and health checks.
  • Involves a follow-up kidney biopsy at week 52 to see if tissue health has improved.
  • Participation is voluntary, and you can withdraw at any point.

Who may be eligible?

You may be able to join this study if you are 18 or older and have a confirmed diagnosis of IgA nephropathy that was verified by a kidney biopsy. You also need to have reasonably stable kidney function, which doctors check using a routine blood test called eGFR.

You will not be able to take part if you are pregnant or breastfeeding, or if you have another chronic kidney disease alongside IgA nephropathy. People with very low levels of certain antibodies or uncontrolled high blood pressure cannot join.

Additionally, you cannot take part if you have recently taken strong steroid tablets or other medicines that suppress your immune system within the past six months (24 weeks), as these could interfere with the study results.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or over.
  2. I have been diagnosed with IgA nephropathy through a kidney biopsy.
  3. My kidney function is relatively stable (eGFR above 45).
  4. I am not pregnant or breastfeeding.
  5. I have not taken strong steroid tablets or immune-suppressing drugs in the last 6 months.
  6. My blood pressure is well-controlled.
Answer every question to see your result.

What does participation involve?

Taking part lasts for just over a year (at least 52 weeks). During the trial, you will attend regular clinic visits where the medical team will check your blood pressure, test your blood and urine, and give you the study medicine, sibeprenlimab. Because this is an open-label trial, there is no dummy drug (placebo); all participants receive sibeprenlimab. At the 52-week mark, you will have a repeat kidney biopsy, where a doctor takes a tiny sample of kidney tissue using a thin needle while the area is numbed, so they can examine the tissue under a microscope. After the main treatment period, there will be follow-up checks to monitor your health.

Potential risks and benefits

You may benefit from receiving a promising new treatment and having your kidney health closely monitored by specialists throughout the year. However, the study medicine may cause side effects, and having a kidney biopsy carries small risks such as temporary bleeding, soreness, or infection. You are completely free to leave the trial at any point, and choosing to stop will never affect your regular NHS care.

Locations (19)

  • University of Alabama at Birmingham
    Verified postcode
    Birmingham, United States
  • Stanford University Medical Center
    Verified postcode
    Stanford, United States
  • Colorado Kidney Care PC
    Verified postcode
    Denver, United States
  • Massachusetts General Hospital (MGH) Harvard
    Verified postcode
    Boston, United States
  • Dakota Dunes
    Verified postcode
    Dakota Dunes, United States
  • Prolato Clinical Research Center
    Verified postcode
    Houston, United States
  • Hospital Britanco de Buenos Aires
    Verified postcode
    Buenos Aires, Argentina
  • Centro Medico Dra Laura Maffei- Investigacion Clinica Aplicada
    Verified postcode
    Buenos Aires, Argentina
  • St. Paul's Hospital
    Verified postcode
    Vancouver, Canada
  • Hamilton Centre for Kidney Research (HCKR)
    Verified postcode
    Hamilton, Canada
  • OTT Healthcare
    Verified postcode
    Scarborough Village, Canada
  • Juntendo University - Urayasu Hospital
    Verified postcode
    Urayasu, Japan

Common questions

Will I definitely receive the study medicine?

Yes. This is an open-label study, meaning there is no placebo (dummy drug), so every participant receives sibeprenlimab.

What happens during a kidney biopsy?

A doctor uses a local anaesthetic to numb your lower back, then uses an ultrasound scan to guide a tiny needle into the kidney to take a small tissue sample.

Can I keep taking my everyday medicines?

Many regular medicines, like blood pressure tablets, are allowed. However, strong steroid pills and other immune-suppressing drugs are not permitted during the study.

Does it cost anything to take part?

No. The study medication, clinic appointments, and tests are provided free of charge, and trial organisers often help cover travel expenses.

What happens if I decide to withdraw from the trial?

You can leave the study at any time without giving a reason. Your standard medical care and relationship with your doctors will stay exactly the same.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.